• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cellulitis - Pipeline Review, H2 2012 Product Image

Cellulitis - Pipeline Review, H2 2012

  • Published: December 2012
  • 40 pages
  • Global Markets Direct

Cellulitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cellulitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cellulitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulitis. Cellulitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cellulitis.
- A review of the Cellulitis products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cellulitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cellulitis 7
Cellulitis Therapeutics under Development by Companies 9
Cellulitis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Cellulitis Therapeutics – Products under Development by Companies 13
Cellulitis Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Cellulitis Therapeutics Development 15
Trius Therapeutics, Inc. 15
Durata Therapeutics Inc. 16
Cellulitis – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
dalbavancin - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
torezolid - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
moxifloxacin hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cefazolin + Probenecid - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Trimethoprim + Sulfamethoxazole + Clindamycin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cellulitis Therapeutics – Drug Profile Updates 31
Cellulitis Therapeutics - Dormant Products 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Cellulitis, H2 2012 7
Products under Development for Cellulitis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Trius Therapeutics, Inc., H2 2012 15
Durata Therapeutics Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Cellulitis Therapeutics – Drug Profile Updates 31
Cellulitis Therapeutics – Dormant Products 38

List of Figures
Number of Products under Development for Cellulitis, H2 2012 7
Products under Development for Cellulitis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos